Sentence examples for complex of type from inspiring English sources

A new, chiral bidentate Ti(IV) complex of type 1 was successfully designed and can be utilized for simultaneous coordination to aldehyde carbonyls, thereby allowing the precise enantioface discrimination of such carbonyls for a new catalytic, practical enantioselective allylation of aldehydes with allyltributyltin.

Bone morphogenetic protein signals through a heteromeric complex of type I and type II transmembrane serine/threonine kinase receptors.

The receptor complex of type III IFNs is composed of the IL-10 receptor beta (IL-10Rβ) and a novel IL-28 receptor alpha (IL-28Rα).

The TGF-β superfamily of ligands signal by binding a complex of type 1 and type 2 receptors and mediating phosphorylation of down-stream SMAD transcription factors to impact on gene transcription.

In an attempt at preparing a cationic AuI complex of type 2, neutral complexes 6 and 7 a were treated with AgSbF6 at 23 °C in the presence of acetonitrile, benzonitrile, or 2,4,6-trimethoxybenzonitrile.

An η-cyclopentadiene complex of type 36 has also been characterised (L = Bu t 2PC6H4-2-Ph 2PC6H4-2-Ph 2PC6H4-2-PhuCl and AgSbF6 were found to polymixturesyclofentadiene and 1,3-cyclohexadiene.

Complexation of these ligands with vanadyl(IV) sulphate leads to the formation of new oxovanadium(IV) complexes of type VIVOL.H2O.

Removal of all halogen atoms from complexes [3] and [4] with AgBF4 in acetonitrile yielded dinuclear iridium III) and rhodium III) complexes of type [Cp*(MeCN 2M benzodicarbene)M(MeCN 2Cp*](BF4)2 [10](BF4)4–[11](BF4)4.

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β family (TGFβ), which signal through hetero-tetrameric complexes of type I and type II receptors.

As can be seen in Fig. 3, while the correspondence clusters-complexes (of type PC1) is still acceptable, the percentages of subunits detected for the complexes are drastically reduced with respect to E.coli.

TGF β ligands bind to heterotetrameric complexes of type I and type II receptors of TGF β (TGF βRII and TGF βRI), activate TGF βRI to phosphorylate SMAD2 and/or SMAD3.